Literature DB >> 6982131

Carbamylcholine modulation of E-rosette formation. Effect of plasmapheresis in myasthenia gravis.

Y Mizuno, J Humphrey, H M Dosch, E W Gelfand.   

Abstract

Myasthenia gravis may result from a reduction of available acetylcholine receptors at the neuromuscular junction, likely secondary to the presence of anti-acetylcholine receptor antibodies. Since T lymphocytes appear to carry a similar nicotinic acetylcholine receptor, we investigated the capacity of T cells from patients with myasthenia gravis to bind sheep erythrocytes. In addition we determined the effect of carbachol, a cholinergic agonist, on E-rosette formation, and the role of myasthenic serum in modulating these responses. Two groups of patients were identified; one with normal numbers of E-rosettes forming cells (E-RFC) and the other with significantly reduced numbers. The majority of patients with myasthenia had a reduced number of carbachol-sensitive T cells. Incubation of their serum (or the IgG fraction) with normal T cells led to a reduction in numbers of E-RFC, particularly of the carbachol-sensitive subset. These effects were blocked by d-tubocurarine and not by atropine. Following plasmapheresis, normal numbers of E-RFC were detected in the patients and the serum inhibitory activity was no longer detected. The data suggest that in parallel to the achievement of some degree of clinical improvement, plasmapheresis may restore some aspects of lymphocyte function.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982131      PMCID: PMC1536643     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Cellular immunity in myasthenia gravis. Response to purified acetylcholine receptor and autologous thymocytes.

Authors:  D P Richman; J Patrick; B G Arnason
Journal:  N Engl J Med       Date:  1976-03-25       Impact factor: 91.245

Review 2.  Myasthenia gravis (first of two parts).

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1978-01-19       Impact factor: 91.245

3.  Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.

Authors:  P C Dau; J M Lindstrom; C K Cassel; E H Denys; E E Shev; L E Spitler
Journal:  N Engl J Med       Date:  1977-11-24       Impact factor: 91.245

4.  The E-rosette assay: a cautionary note.

Authors:  E W Gelfand; A Shore; B Green; M T Lin; H M Dosch
Journal:  Clin Immunol Immunopathol       Date:  1979-01

Review 5.  Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model.

Authors:  J Lindstrom
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

6.  Identification of two serum components regulating the expression of T-lymphocyte function in childhood myasthenia gravis.

Authors:  A Shore; S Limatibul; H M Dosch; E W Gelfand
Journal:  N Engl J Med       Date:  1979-09-20       Impact factor: 91.245

7.  Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange.

Authors:  J Newsom-Davis; A J Pinching; A Vincent; S G Wilson
Journal:  Neurology       Date:  1978-03       Impact factor: 9.910

8.  Remission of myasthenia gravis following plasma-exchange.

Authors:  A J Pinching; D K Peters
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

9.  Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs.

Authors:  R Tarrab-Hazdi; A Aharonov; O Abramsky; I Yaar; S Fuchs
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.